A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.
from Dementia Big http://ift.tt/2DF8hWL via alcoholic dementia
http://ift.tt/2FdEm4o
No comments:
Post a Comment